TScan Therapeutics (NASDAQ:TCRX) Stock Rating Reaffirmed by Wedbush

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a research note issued to investors on Wednesday, RTT News reports. They presently have a $10.00 target price on the stock. Wedbush’s price target would suggest a potential upside of 47.71% from the company’s current price.

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Thursday, March 7th.

TScan Therapeutics Stock Down 5.0 %

TScan Therapeutics stock traded down $0.36 during mid-day trading on Wednesday, hitting $6.77. 1,503,910 shares of the company’s stock were exchanged, compared to its average volume of 183,401. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.18. The stock has a market cap of $324.15 million, a P/E ratio of -3.64 and a beta of 0.90. TScan Therapeutics has a 1-year low of $1.62 and a 1-year high of $9.00. The stock has a 50 day moving average of $7.00 and a two-hundred day moving average of $5.62.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.08. The firm had revenue of $7.21 million for the quarter, compared to the consensus estimate of $2.94 million. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. As a group, analysts anticipate that TScan Therapeutics will post -1.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pale Fire Capital SE bought a new position in TScan Therapeutics during the third quarter worth about $42,000. Letko Brosseau & Associates Inc. acquired a new stake in shares of TScan Therapeutics during the third quarter worth approximately $83,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of TScan Therapeutics during the fourth quarter worth approximately $129,000. Virtu Financial LLC acquired a new stake in shares of TScan Therapeutics during the fourth quarter worth approximately $107,000. Finally, State Street Corp increased its holdings in shares of TScan Therapeutics by 60.4% during the second quarter. State Street Corp now owns 38,500 shares of the company’s stock worth $96,000 after buying an additional 14,500 shares in the last quarter. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.